Transform how you analyse drug development risk
With the only transparent analysis of drug development risk at the product level.
The Vantage 2019 Preview looks at the risks and opportunities for the year ahead.
Following a sharp downturn in late 2018, the Pharma and Biotech sectors are entering 2019 in a state of uncertainty.
Investors are nervous, so are likely to become more cautious and selective in their choices. The potential upside of this could be a rallying M&A market as valuations drop, but data-led proof could be the key to attracting financing.